ClinicalTrials.gg
TerminatedNCT00331604Updated Mar 1, 2017

Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes

A Phase 3 interventional study of inhaled human insulin and insulin detemir in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 73 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-03-01.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
618
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
4th of 49
618 · median 129
Started
2006
with 9 others
Phase 3
25 of 49
none open now
Registered
5th of 49
by date
Lead sponsor
10 of 49
Novo Nordisk A/S

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 10 that started in 2006, is one of 25 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This trial is conducted in Asia, Europe and South America. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function tests, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin detemir in Type 2 Diabetes.

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 618 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Currently treated with insulin
  • of (BMI) less than or equal to 40.0 kg/m2
  • less than or equal to 11.0%

Exclusion criteria

Exclusion Criteria:

  • Total daily insulin dosage less than or equal to 100 IU or U/day
  • Current smoking or smoking within the last 6 months
  • Cardiac problems
  • Uncontrolled hypertension
  • Current proliferative retinopathy or maculopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
618 participants (actual)

Study arms

  • Experimental
    A

    Drug: inhaled human insulin · Drug: insulin detemir

  • Active comparator
    B

    Drug: insulin detemir · Drug: insulin aspart

  • Active comparator
    C

    Drug: insulin detemir · Drug: insulin aspart

Interventions

07

What researchers measure

Primary outcomes

  1. Treatment difference in HbA1c

    Time frame: After 52 weeks

Secondary outcomes

  1. Adverse events

    Time frame: For the duration of the trial

  2. Blood glucose

    Time frame: After 52, 104 and 116 weeks of treatment

  3. Body weight

    Time frame: During treatment

  4. Lung function

    Time frame: After 52, 104 and 116 weeks of treatment

  5. Hypoglycaemia

    Time frame: From 12 weeks of treatment

08

Study locations

73 sites
  • Novo Nordisk Investigational Site
    Campinas, 13083-900, Brazil
  • Novo Nordisk Investigational Site
    Higienopolis, 01244-030, Brazil
  • Novo Nordisk Investigational Site
    Porto Alegre, 90035-170, Brazil
  • Novo Nordisk Investigational Site
    Sao Paulo, 04022-001, Brazil
  • Novo Nordisk Investigational Site
    Hillerød, 3400, Denmark
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Brest, 29200, France
  • Novo Nordisk Investigational Site
    GRENOBLE cedex, 38043, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    NEVERS cedex, 58033, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67091, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Bad Harzburg, 38667, Germany
  • Novo Nordisk Investigational Site
    Bad Kreuznach, 55545, Germany
  • Novo Nordisk Investigational Site
    Bad Lauterberg, 37431, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01219, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 21073, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Herrenberg, 71083, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Neumünster, 24534, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Schkeuditz, 04435, Germany
  • Novo Nordisk Investigational Site
    Speyer, 67346, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Warburg, 34414, Germany
  • Novo Nordisk Investigational Site
    Shatin, New Territories, Hong Kong
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Bari, 70124, Italy
  • Novo Nordisk Investigational Site
    Catania, 95122, Italy
  • Novo Nordisk Investigational Site
    Catanzaro, 88100, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Perugia, 06126, Italy
  • Novo Nordisk Investigational Site
    Pescara, 65124, Italy
  • Novo Nordisk Investigational Site
    Pisa, 56100, Italy
  • Novo Nordisk Investigational Site
    Roma, 00133, Italy
  • Novo Nordisk Investigational Site
    Roma, 00168, Italy
  • Novo Nordisk Investigational Site
    San Giovanni Rotondo, 71013, Italy
  • Novo Nordisk Investigational Site
    Verona, 37126, Italy
  • Novo Nordisk Investigational Site
    Singapore, 119074, Singapore
  • Novo Nordisk Investigational Site
    Singapore, 159964, Singapore
  • Novo Nordisk Investigational Site
    Almería, 04001, Spain
  • Novo Nordisk Investigational Site
    Cáceres, 10004, Spain
  • Novo Nordisk Investigational Site
    Elche, 3203, Spain
  • Novo Nordisk Investigational Site
    Granada, 18012, Spain
  • Novo Nordisk Investigational Site
    Lugo, 27004, Spain
  • Novo Nordisk Investigational Site
    Mostoles - Madrid -, 28935, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41014, Spain
  • Novo Nordisk Investigational Site
    Valladolid, 47011, Spain
  • Novo Nordisk Investigational Site
    Xátiva, 46800, Spain
  • Novo Nordisk Investigational Site
    Taichung City, 407, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 100, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 114, Taiwan
  • Novo Nordisk Investigational Site
    Aberdeen, AB25 1LD, United Kingdom
  • Novo Nordisk Investigational Site
    Ayr, KA6 6DX, United Kingdom
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Cosham, PO6 3LY, United Kingdom
  • Novo Nordisk Investigational Site
    Edgbaston, Birmingham, B15 2TH, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH16 4SA, United Kingdom
  • Novo Nordisk Investigational Site
    Livingstone, EH54 6PP, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL6 8BQ, United Kingdom
  • Novo Nordisk Investigational Site
    Salford, M6 8HD, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Wirral, Merseyside, CH63 4JY, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2006 to primary completion in May 2008, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2006
First posted
May 31, 2006
StartActual
Aug 31, 2006
Primary completionActual
May 5, 2008
CompletionActual
May 5, 2008
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00331604
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 31, 2006
Start date
Aug 31, 2006
Primary completion
May 5, 2008
Completion
May 5, 2008
Last update
Mar 1, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion